3 Big Pharmaceuticals Investing in Smaller Antibodies Motley Fool Antibodies should comprise roughly half of the ten highest selling drugs over the next several years. Although they're incredibly effective, they're also very difficult to work with. A small biotechnology company named Ablynx in Belgium may have found ... |
